Passive immunotherapy -for example, using specific antibodiesmay represent a good possible treatment strategy against Middle East respiratory syndrome corona virus (MERSCoV). However, producing largeenough quantities of such antibodies is economically and logistically challenging. In a new study, Luke et al. use trans chromosomic (Tc) bovines to produce human antiMERSCoV antibodies that show efficacy in vitro and in a mouse model of MERSCoV infection.
The authors used cattle that lack bovine immunoglobulin (Ig) genes and instead carry a human artificial chromosome bearing the genes encoding human Ig heavy chain and κlight chain proteins, with a bias for producing IgG1 subclass antibodies. Following vaccination, these animals can each produce 150-600 g of human polyclonal IgG antibodies per month.
Next, the authors created two different MERSCoV vaccines: a wholekilled Jordan strain virion vaccine (WKVV) and an AlHasa strain spike protein nanoparticle vaccine (SPNV). Tc bovines were vaccinated every 21-28 days on five occasions (V1-V5) with WKVV or SPNV. Two human polyclonal IgG products -named SAB300 or SAB301, respectively -were purified from the hyperimmune plasma collected from the animals after V2, V3, V4 and V5. In vitro, pretreatment of Jordan strain MERSCoV with SAB300 or SAB301 before culturing with Vero E6 kidney epithelial cells markedly reduced virusinduced cytopathy, implying that these antibodies neutralize MERSCoV.
Antibodydependent enhance ment of infection -whereby anti bodies facilitate the entry of viruses into cells that do not carry the usual entry receptor for the virus -has been suggested to occur following the use of some antiCoV vaccines. Here, the authors treated Jordan strain MERSCoV with SAB300 or SAB301 before incubating the virus with Raji cells -human B cells that lack dipeptidyl peptidase 4 (DPP4; the MERSCoV entry receptor) and that therefore are not permissive to MERSCoV. Levels of MERSCoV specific RNA transcripts in the Raji cells 48 hours later were not increased by pretreatment with either SAB300 or SAB301, implying that these treatments do not facilitate virus entry into these cells.
Although mice do not typically express DPP4 and so are resistant to MERSCoV infection, transduc tion of mice with a human DPP4 expressing adenovirus (AdhDPP4 mice) confers susceptibility. The authors intraperitoneally injected AdhDPP4 mice with SAB301 or a control human IgG and, 12 hours later, intranasally infected them with MERSCoV. By day 5 postinfection, viral titers in the lung of SAB301 treated mice, but not of controls, were below the limit of detection. SAB301 treatment of AdhDPP4 mice 24 hours after MERSCoV exposure also reduced lung viral titers 5 days later to below the limit of detection. Thus, a single treatment of SAB301 can be effective either prophylactically or after exposure to MERSCoV.
This study demonstrates how large quantities of human MERSCoVneutralizing antibodies can be rapidly produced in Tc bovines, thus providing a possible strategy for the development of passive immunotherapies against coronaviruses or other new and emerging infectious diseases.
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